Compare MUX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | ARVN |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 600.2M |
| IPO Year | 1994 | 2018 |
| Metric | MUX | ARVN |
|---|---|---|
| Price | $9.17 | $6.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $28.40 | $14.00 |
| AVG Volume (30 Days) | ★ 1.3M | 924.3K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | 0.10 | ★ 0.88 |
| Revenue | $197,553,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $19.23 | $5.67 |
| Revenue Next Year | $34.88 | N/A |
| P/E Ratio | $96.10 | ★ $7.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.59 | $6.33 |
| 52 Week High | $29.70 | $14.20 |
| Indicator | MUX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 22.06 | 37.17 |
| Support Level | N/A | N/A |
| Resistance Level | $20.62 | $7.85 |
| Average True Range (ATR) | 0.82 | 0.45 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 0.34 | 11.78 |
McEwen Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. Its Other operations include: Fox Complex, Gold Bar Complex, Project Fenix, and Los Azules. The company generates its revenue from gold and silver production. Its operating segments include Canada, United States, Mexico, MSC and McEwen Copper, of which it derives maximum revenue from USA.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.